Spironolactone is NOT recommended at eGFR 28 mL/min/1.73 m² in HFpEF
With an eGFR of 28 mL/min/1.73 m², spironolactone should be avoided in this patient with HFpEF due to unacceptable risk of life-threatening hyperkalemia and worsening renal function. The 2013 ACC/AHA Heart Failure Guidelines explicitly classify this as Class III: Harm, stating that aldosterone receptor antagonists are "potentially harmful because of life-threatening hyperkalemia or renal insufficiency when estimated glomerular filtration rate <30 mL/min/1.73 m²" 1.
Why This eGFR is Contraindicated
The evidence is unequivocal across multiple guidelines:
- 2013 ACC/AHA Guidelines: Spironolactone is contraindicated when eGFR <30 mL/min/1.73 m² 1
- 2017 ACC/AHA Update: Reiterates that eGFR must be >30 mL/min for spironolactone use in HFpEF 2
- FDA Label: For heart failure, spironolactone dosing recommendations only apply when eGFR >30 mL/min/1.73 m² 3
The TOPCAT trial, which showed modest benefit in HFpEF, specifically excluded patients with creatinine >2.5 mg/dL and required eGFR >30 mL/min 2. At eGFR 28, this patient falls below the safety threshold established by clinical trials.
The Hyperkalemia Risk is Prohibitive
At eGFR 28 mL/min/1.73 m², the risk-benefit ratio shifts dramatically against spironolactone:
- Research from TOPCAT-Americas showed that even with eGFR 30-60 mL/min, spironolactone increased hyperkalemia risk substantially 4
- The absolute risk of adverse events requiring drug discontinuation is "amplified in the lower eGFR categories" 4
- With eGFR <30, potassium excretion is severely impaired, making life-threatening hyperkalemia (>5.5 mEq/L) highly likely 1
Common pitfall: Clinicians sometimes attempt low-dose spironolactone (12.5 mg every other day) in advanced CKD, but even this carries unacceptable risk at eGFR 28. The 2013 guidelines note that while every-other-day dosing can be considered for eGFR 30-49 mL/min, this does not extend below 30 1.
What About Newer MRAs?
The 2024 KDIGO CKD Guidelines recommend nonsteroidal MRAs (like finerenone) for patients with type 2 diabetes and eGFR >25 mL/min/1.73 m² 5. However, this patient's eGFR of 28 is:
- Just barely above the 25 threshold
- Subject to the caveat that nonsteroidal MRAs require "normal serum potassium concentration" and "consistent monitoring" 5
- Primarily studied in diabetic CKD, not specifically HFpEF
If this patient has diabetes, finerenone could theoretically be considered with extreme caution and intensive potassium monitoring. However, steroidal MRAs like spironolactone remain contraindicated.
Alternative HFpEF Management at This eGFR
Focus on therapies proven safe and effective in advanced CKD:
SGLT2 inhibitors: The 2024 KDIGO guidelines strongly recommend SGLT2i for heart failure "irrespective of level of albuminuria" with eGFR ≥20 mL/min/1.73 m² 5, 6. This patient at eGFR 28 is an ideal candidate.
Continue RAS inhibitors: ACE inhibitors or ARBs should be continued even when eGFR falls below 30 mL/min/1.73 m² 5, 6
Optimize diuretics: Loop diuretics for volume management remain cornerstone therapy
Blood pressure control: Target appropriate BP without causing symptomatic hypotension
Monitoring Requirements If Spironolactone Were Used (Which It Shouldn't Be)
For academic completeness, if a clinician were to use spironolactone despite contraindication (not recommended):
- Check potassium and creatinine within 2-3 days, then at 7 days 1
- Monthly monitoring for first 3 months, then every 3 months 1
- Discontinue immediately if potassium >5.5 mEq/L 1
- Stop during any acute illness, dehydration, or diarrhea 1
However, this intensive monitoring does not make spironolactone safe at eGFR 28—it remains contraindicated.
The Bottom Line
At eGFR 28 mL/min/1.73 m², the mortality and morbidity risks from hyperkalemia and worsening renal function with spironolactone far outweigh any potential cardiovascular benefit in HFpEF. Prioritize SGLT2 inhibitors, which have strong evidence for both heart failure and CKD protection at this level of renal function 5, 6.